With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trialsNEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that the Bellberry Human Research Ethics Committee (HREC) has formally app ...

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that the Bellberry Human Research Ethics Committee (HREC) has formally approved the use of PsyLabs’ psilocybin product (NPX5) in the Company’s ongoing Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in patients wi ...

Core Insights - Psyence Biomedical Ltd. announced that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract, meeting food-grade microbial safety standards [1][3][4] - The achievement reflects Psyence BioMed's ongoing investment and collaboration with PsyLabs, which aims to develop scalable and compliant psychedelic APIs [1][4] - PsyLabs is focused on increasing purity levels of its products and expanding its chemistry production area to meet growing demand for psychedelic compounds [2][4] Company Overview - PsyLabs is a federally licensed company specializing in the cultivation, extraction, and export of psychedelic compounds, including psilocybin and ibogaine, to legal medical and research markets [6][7] - The company has successfully exported psilocybin products to multiple countries, including Canada, the UK, and Portugal, and supplies purified extracts to its UK-based CMO partner [6][7] - Psyence BioMed is a vertically integrated biopharmaceutical company focused on developing nature-derived psychedelic medicine, particularly for unmet mental health needs [7] Strategic Developments - PsyLabs' extraction division is expanding to ensure consistent production of high-purity psychedelic APIs, including Ibogaine HCL and Psilocybin Isolate [4][5] - The company emphasizes its commitment to refining processes for higher purity levels to support the increasing demand for quality psychedelic APIs [4][5] - PsyLabs aims to provide a reliable and ethically sourced supply of Ibogaine to licensed research institutions and developers worldwide [5]